TY  - JOUR
A1  - Reichetzeder, Christoph
A1  - von Websky, Karoline
A1  - Tsuprykov, Oleg
A1  - Samarin, Azadeh Mohagheghi
A1  - Falke, Luise Gabriele
A1  - Putra, Sulistyo Emantoko Dwi
A1  - Hasan, Ahmed Abdallah Abdalrahman Mohamed
A1  - Antonenko, Viktoriia
A1  - Curato, Caterina
A1  - Rippmann, Joerg
A1  - Klein, Thomas
A1  - Hocher, Berthold
T1  - Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury
JF  - British journal of pharmacology : journal of The British Pharmacological Society
N2  - BACKGROUND AND PURPOSE Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia-reperfusion injury (IRI) are conflicting. Here we have compared structurally unrelated DPP4 inhibitors in a model of renal IRI. EXPERIMENTAL APPROACH IRI was induced in uninephrectomizedmale rats by renal artery clamping for 30 min. The shamgroup was uninephrectomized but not subjected to IRI. DPP4 inhibitors or vehicle were given p. o. once daily on three consecutive days prior to IRI: linagliptin (1.5 mg.kg(-1).day(-1)), vildagliptin (8mg.kg(-1).day(-1)) and sitagliptin (30 mg.kg(-1).day(-1)). An additional group received sitagliptin until study end (before IRI: 30 mg.kg(-1).day(-1); after IRI: 15mg.kg(-1).day(-1)). KEY RESULTS Plasma-active glucagon-like peptide type 1 (GLP(-1)) increased threefold to fourfold in all DPP4 inhibitor groups 24 h after IRI. Plasma cystatin C, a marker of GFR, peaked 48 h after IRI. Compared with the placebo group, DPP4 inhibition did not reduce increased plasma cystatin C levels. DPP4 inhibitors ameliorated histopathologically assessed tubular damage with varying degrees of drug-specific efficacies. Renal osteopontin expression was uniformly reduced by all DPP4 inhibitors. IRI-related increased renal cytokine expression was not decreased by DPP4 inhibition. Renal DPP4 activity at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group. Active GLP(-1) plasma levels at study end were increased only in the prolonged/dose-adjusted sitagliptin treatment group. CONCLUSIONS AND IMPLICATIONS In rats with renal IRI, DPP4 inhibition did not alter plasma cystatin C, a marker of glomerular function, but may protect against tubular damage.
Y1  - 2017
U6  - https://doi.org/10.1111/bph.13822
SN  - 0007-1188
SN  - 1476-5381
VL  - 174
SP  - 2273
EP  - 2286
PB  - Wiley
CY  - Hoboken
ER  -